Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?

NCT ID NCT07757711

Not yet recruiting Knowledge-focused Sponsor: Mario Negri Institute for Pharmacological Research Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study aims to create new laboratory models of ovarian cancer that no longer respond to standard platinum-based chemotherapy or PARP inhibitors. Researchers will take tumor tissue from patients with resistant disease and grow it in mice and in the lab to mimic real clinical conditions. These models could help test new drugs and identify biomarkers that predict treatment response, potentially leading to better strategies for overcoming resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tumor tissue samples from patients with resistant ovarian cancer are used to create experimental models; no drug is given to patients.
What this could lead to: If successful, these models could help identify new drug combinations and biomarkers to overcome therapy resistance in ovarian cancer.
What could go wrong: This is an early-stage research study focused on model development, not a treatment trial. The models may not fully replicate human disease, and findings may not translate to patient benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.